Shocking Study Reveals COVID-19 Vaccine Ingredient Could Fuel Cancer Growth
Meanwhile, leading cancer research organization gives 2024 Outstanding Achievement Award for Service to Cancer Science and Medicine to Pfizer Chairman and CEO Dr. Albert Bourla.
Groundbreaking study reveals potential cancer-promoting effects of m1Ψ-modified mRNA vaccines.
The rapid deployment of mRNA vaccine technology, spotlighted by the COVID-19 crisis, has brought to light the potential dual nature of N1-methyl-pseudouridine (m1Ψ) modifications in these vaccines. Initially heralded for their ability to enhance vaccine efficacy and safety by stabilizing mRNA and reducing immunogenicity, recent evidence suggests a darker side to m1Ψ, particularly in the context of cancer.
A study focusing on the impact of m1Ψ-modified mRNA vaccines in a melanoma model found that while traditional, non-modified mRNA vaccines inhibited cancer growth and metastasis, those containing 100% m1Ψ modification appeared to stimulate cancer progression. This alarming discovery is attributed to m1Ψ's capability to dampen early interferon signaling, a critical component of the immune response, thus potentially facilitating an environment conducive to cancer development.
In 2020, the Pfizer vaccine made history as the first fully licensed mRNA vaccine. To achieve this, m1Ψ was included in Pfizer-BioNTech's COVID-19 mRNA vaccine (Comirnaty® or BNT162b2), which encodes the complete transmembrane spike (S) protein of SARS-CoV-2. Through extensive in vitro transcription (IVT), a substantial amount of m1Ψ-modified mRNA for the SARS-CoV-2 (COVID-19) spike protein was produced.
2024 AACR Outstanding Achievement Award to Pfizer CEO Dr. Albert Bourla Raises Concerns Over Research Integrity
The American Association for Cancer Research (AACR) recently announced that it awarded the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine to Pfizer Inc. and its chairman and chief executive officer, Dr. Albert Bourlaat the AACR Annual Meeting 2024, which took place from April 5-10 in San Diego, California. The award was presented during the Opening Ceremony on Sunday, April 7, where Dr. Bourla accepted it and delivered remarks.
The award to Pfizer and Dr. Bourla was meant to recognize their contributions to oncology and their partnership with the AACR over the years. In December 2023, Pfizer had donated the U.S. royalties from the sale of Bavencio® (avelumab) to the AACR, intended to support the organization's cancer research mission.
However, this recognition and financial relationship between Pfizer and the AACR have brought forward concerns regarding the potential conflict of interest and the integrity of cancer research sponsored by the AACR. Critics argue that accepting significant donations from a pharmaceutical company could influence the objectivity of the AACR, especially in light of recent studies suggesting that mRNA vaccines developed by companies like Pfizer, which utilize modified RNA (modRNA), could potentially contribute to cancer growth.
These concerns are fueled by recent scientific discussions about the long-term effects of mRNA technology, particularly in the context of oncology.
The celebration of Pfizer's contributions by the AACR has therefore sparked a debate about the balance between industry partnerships and maintaining research integrity. Critics suggest that the AACR's financial ties with Pfizer could cast a shadow over its commitment to unbiased cancer research, calling for greater transparency and scrutiny in how research agendas are set and funded.
Looking for a holistic practitioner? Check out the Wholistic Clinic.
Thanks for the info. However there was never a 'COVID-19 crisis' as the entire 'pandemic' narrative was fabricated on the basis of lies, fraud and fearmongering.
From today- Reuters: April 9th 2024
Moderna jumps as personalized cancer vaccine shows benefit in early study . Meet the newest and best. Moderna shares rose 8% ... same bird , different wing. Who owns Reuters anyway- maybe some Cartel of sorts ?